FDA grants conditional acceptance of LYRFIGTU brand name
Elevar Therapeutics says the FDA granted conditional acceptance of LYRFIGTU as the brand name for lirafugratinib, which is under FDA Priority Review.
, Ltd. S. Food and Drug Administration has granted conditional acceptance of LYRFIGTU as the brand name for lirafugratinib, which is currently under FDA Priority Review as a treatment option.